Therapeutic Asset Ratings
124 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ulixertinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Taselisib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(51)
Atezolizumab
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CCC
(50)
Durvalumab
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1/2
CCC
(50)
Niraparib
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CCC
(50)
Tuvusertib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P1/2
CCC
(50)
Capecitabine
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CCC
(49)
Irinotecan
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CCC
(49)
Entinostat
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P1/2
CCC
(49)
Bms-907351
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1
CCC
(48)
Devimistat
Advanced Malignant Solid Neoplasm
Northwestern University
P2
CC
(47)
FMISO
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CC
(47)
Eribulin
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CC
(46)
(+)-VINCRISTINE
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CC
(46)
Axatilimab
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
Decitabine
Advanced Malignant Solid Neoplasm
Roswell Park Cancer Institute
P1/2
CC
(45)
HAFNIUM OXIDE
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1/2
CC
(45)
Ivuxolimab
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1/2
CC
(45)
Retifanlimab
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
trc102
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P1/2
CC
(45)
Pamiparib
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1
CC
(44)
Utomilumab
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1/2
CC
(44)
Avelumab
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1/2
CC
(43)
au409
Advanced Malignant Solid Neoplasm
University of Southern California
P1
CC
(41)
Axitinib
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P1
CC
(41)
Showing 76 to 100 of 124 assets
Previous
Page 4 of 5
Next